BSH 2023 | Updates in the treatment of R/R LBCL: promising novel agents in the pipeline
Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discusses exciting updates in the treatment and management of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Dr Osborne highlights promising agents in the pipeline, including tafasitamab-lenalidomide and loncastuximab tesirine (lonca-T), and emphasizes the importance of determining the optimal sequencing of these agents. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Roche, Takeda, Pfizer, Servier, Kite Gilead, MSD, Novartis, Beigene, Astra Zeneca, Syneos, Autolus, Kyowa Kirin, Abbvie, Incyte, BMS/Celgene, Janssen
